The use of liposomes as snake venom vehicles: Application in protective immunization

Journal of Toxicology - Toxin Reviews

Volumn 17, Issue 4, 1998, Pages 441-466

  Freitas, T V ^a   Diniz, C R ^a   Frezard F ^a  

^a FUNDAÇÃO EZEQUIEL DIAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DRUG VEHICLE; IMMUNOMODULATING AGENT; LIPOSOME; PHOSPHOLIPID; SNAKE VENOM;

ACTIVE IMMUNIZATION; ANIMAL DISEASE; BILAYER MEMBRANE; DRUG DELIVERY SYSTEM; HUMAN; IMMUNITY; MORTALITY; NONHUMAN; REVIEW;

ANIMALIA; SERPENTES;

EID: 0032412928     PISSN: 07313837     EISSN: None     Source Type: Journal    
DOI: 10.3109/15569549809040403     Document Type: Review

References (68)

1. Ostro MJ. Introduction. In: Ostro MJ (Editor), Liposomes: from biophysics to therapeutics, vii, Marcel Dekker, Inc., New York, 1987.
2. New RRC. Introduction. In: New RRC (Editor), Liposomes a practical approach, 1, Irl Press, Oxford, New York, Tokyo, 1990.
3. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunology Today, 11:89-97, 1990.
4. Papahadjopoulos D. A new perspective on liposomes. Journal of Liposome Research, 2: iii-xviii, 1992.
5. New RRC, Theakston RDG, Zumbuehl O, Iddon D & Friend J. Immunization against snake venom. New England Journal of Medicine, 311: 56-57, 1984.
6. New RRC, Theakston RDG, Zumbuehl O, Iddon D & Friend J. Liposomal immunization against snake venom. Toxicon, 23: 215-219, 1985.
7. Theakston RDG, Zumbuehl O & New RRC. Use of liposomes for protective immunization in sheep against Echis carinatus snake venom. Toxicon, 23: 921-925, 1985.
8. Laing G, Theakston RDG, New RRC, Zumbuehl O & Parsley A. Use of venom incorporating immunostimulant for immunization against snake venom. Transactions of the Royal Society of Tropical Medicine and Hygiene, 80: 338, 1986.
9. Laing G, Theakston RDG & New RRC. Use of liposomes incorporating immunostimulant for parenteral and oral immunization against snake venom. In: Gopalakrishnakone P & Tann CK (Editors), Progress in venom and toxin research. pp. 283-295. Singapore, 1987.
10. Freitas TV, Tavares AP, Theakston RDG, Laing G & New RRC. Use of liposomes for protective immunization against Crotalus durissus terrificus (tropical rattlesnake) venom. Toxicon, 27: 341-347, 1989.
11. Romanova EB, Gevashvili DB, Koshkina NV & Torchilin VP. Toxicity and immunogenic properties of liposomal form of Vipera libetina venom. Journal of Liposome Research, 2: 205-216, 1992.
12. Laing G & Theakston RDG. Immunization against Echis ocellatus (Carpet viper) venom using liposomes incorporating immunostimulants: role of lipopolysaccharide in conferring protection in a mouse model. Toxicon, 31: 615-626, 1993.
13. Gruner SM. Material properties of liposomal bilayers. In: Ostro MJ (Editor), Liposomes: from biophysics to therapeutics, 1, Marcel Dekker, Inc., New York, 1987.
14. Crowe LM, Crowe JH, Rodolph A, Womersley C & Appel L. Preservation of freeze-dried liposomes by trehalose. Archives of Biochemistry and Biophysics, 242: 240-247, 1985.
15. Stewart MJ, Plautz GE, Del Buono L, Yang ZY, Xu L, Gao X, Huang L, Nabel EG & Nabel GJ, Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Human Gene Therapy, 3: 267-275, 1992
16. Wang CY, Huang L, pH-sensitive immunoliposomes mediated target-cell-specific delivery and controlled expression of a foreign gene in mouse. Proceeding National Academic Science USA, 84: 7851-7855, 1987
17. Gregoriadis G & Florence AT. Liposomes in drug delivery. Clinical, diagnostic and ophthalmic. Drugs, 45: 15-28, 1993.
18. + permeability, active doxorubicin encapsulation and stability in human serum. Biochimica Biophysica Acta, 1194: 61-68, 1994.
19. Riess JG, Frézard F, Greiner J, Kraft MP, Santaella C, Vierling P & Zarif L. Membranes, vesicles and other supramolecular systems made from fluorinated amphiphiles. In:Barenholz Y & Lasic D (Editors), Handbook of non-medical applications of liposomes, (III) 8, CRC Press Inc., 1996.
20. Frézard F, Santaella C, Vierling P & Riess JG. Permeability and stability in buffer and in human serum of fluorinated phospholipid-based liposomes. Biochimica et Biophysica Acta, 1192: 61-70, 1994.
21. Vierling P, Santaella C & Riess JG). Fluorinated liposomes. In: Puisieux F, Couvreur P, Delattre J & Devissaguet JP (Editors), Liposomes, new systems and new trends in their applcations, 293, Editions de Santé, Paris, 1995.
22. Kirby C & Gregoriadis G. Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology, 2: 979-984, 1984.
23. Crowe JH, Hoekstra FA & Crowe LM. Anhydrobiosis. Annual Review of Physiology, 54: 579-599, 1992.
24. Friede M, van Regenmortel MHV & Schuber F. Liophilized liposomes and shelf items for the preparation of immunogenic liposome-peptide conjugates. Analytical Biochemistry, 211: 117-122, 1993.
25. Crowe LM & Crowe JH. Freeze-dried liposomes. In: Puisieux F, Couvreur P, Delattre J & Devissaguet JP (Editors), Liposomes, new systems and new trends in their applications, 237, Editions de Santé, Paris, 1995.
26. Szoka F & Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proceedings of the National Academy of Sciences of the United States of America, 75: 4194-4198, 1978.
27. Shew RL & Deamer DW. A novel method for encapsulation of macromolecules in liposomes. Biochimica et Biophysica Acta, 816: 1-8, 1985.
28. Tan L, Loyter A & Gregoriadis G. Incorporation of reconstituted influenza virus envelopes into liposomes: studies of the immune response in mice. Biochemical Society Transactions, 17: 129-130, 1989.
29. Gregoriadis G. The carrier potential of liposomes in biology and medicine. New England Journal of Medicine, 295: 704-710, 1976.
30. Fattal E, Ramaldes GA & Ollivon M. Oral delivery of vaccines by means of liposomes. In: Puisieux F, Couvreur P, Delattre J & Devissaguet JP (Editors), Liposomes, new systems and new trends in their applcations, 1995.
31. Lasic DD & Papahadjopoulos D. Liposomes revisited. Science, 267: 1275-1276, 1995.
32. Santaella C, Frezard F, Vierung P & Riess JG. Extended in vivo blood circulation time of fluorinated liposomes. Federation of European Biochemical Societies Letters, 336: 481-484, 1993.
33. Gregoriadis G, Garcon N, Senior J & Davis D. The immunoadjuvant action of liposomes: nature of immune response and influence of liposomal characteristics. In: Gregoriadis G (Editor), Liposomes as drug carriers, John Wiley and Sons, 1988.
34. Buiting AMJ, van Rooijen N & Claassen E. Liposomes as antigen carriers and adjuvant in vivo. Research in Immunology, 143: 541-548, 1992.
35. Perrin P. Liposomes et vaccins. In: Delattre J, Couvreur P, Puisieux F, Philipot JR & Shubert F (Editors), Les Liposomes -aspects technologiques, biologiques et pharmacologiques, 225, Paris, 1993.
36. van Rooijen N & van Nieuwmegen R. Liposomes in immunology: evidence that their adjuvant effect results from surface exposition of the antigens. Cellular immunology, 49: 402-407, 1980.
37. Antimisiaris SG, Jayasekera P & Gregoriadis G. Liposomes as vaccine carriers: incorporation of soluble and particulate antigens in giant vesicles. Journal of Immunological Methods, 166: 271-280, 1993.
38. Petrov, A.B.; Semenov, B.F.; Vartanyan, Y.P.; Zakirov, M.M.; Torchilin, V.P.; Trubetskoy, V.S. and Dmitriev, B.A. Toxicity and immunogenicity of Neisseria meningitidis lipopolysaccharide incorporated into liposomes Infection and Immunity, 60: 3897-3903, 1992.
39. Barratt G & Morin C. Liposomal immunomodulators. In: Puisieux F, Couvreur P, Delattre J & Devissaguet JP (Editors), Liposomes, new systems and new trends in their applcations, 461, Editions de Santé, Paris, 1995.
40. Moran AP. Structure-bioactrvity relationships of bacterial endotoxins. Journal of Toxicology. Toxin Reviews, 14:47-83, 1995.
41. Ellouz F, Adam A, Ciorbaru R & Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochemical and Biophysical Research Communications, 59: 1317-1325, 1974.
42. Alving CR. Lipopolysaccharide, lipid A and liposome containing lipid A as immunological adjuvants. Immunbiology, 187: 430-446, 1993.
43. Grasset E. Anavenoms and their use in the preparation of antivenoms sera. Transactions of the Royal Society of Tropical Medicine and Hygiene 38: 463-488, 1945.
44. Relyveld EH, Girard O, Cheyroux M, Asso J & De Rudder J. Noveau procedé d'inactivation pour la preparation de vacines. Developments in Biological Standardization, 27: 236-348, 1974.
45. Okonogi T, Hattori Z, Ogiso A & Mitsui S. Detoxification by persimmon tannin of snake venoms and bacterial toxins. Toxicon 17: 524-527, 1979.
46. Cardi BA & Andrade Jr. HF. Aumento do reconhecimento e fagocitose por macrófagos de crotoxina de C. d. terrificus após irradiação gama. In: Congresso da Sociedade Brasileira de Medicina Tropical, 31. São Paulo, 1995.
47. Daniel JP, Heneine LGD, Tavares CAP, Nascimento MCS & Neneine IF. Generation of protective immune sera by Crotalus durissus terrificus venom detoxified by controlled iodination. Brazilian Journal of Medical and Biological Research, 20: 713-720, 1987.
48. Bolanos, R & Cerdas L. The production and control of anti-venoms sera. Developments in Biological Standardization, 41: 109-116, 1978.
49. Rolim-Rosa R, Vieira EGJ, Silles-Villaroel M, Siracusa YQ & Yizuka H. Analise comparativa entre os diferentes esquemas de hiperimunização empreados na produção de soros antiofidicos do Instituto Butantan (1957-1979). Memorias do Instituto Butantan, 44-45: 259-265, 1980.
50. Schaeffer RC Jr., Randall H, Resk J & Carlson RW. Enzyme-linked immunosorbent assay (ELISA) of size-selected crotalid venom antigen by Wyeth's polivalent antivenom. Toxicon, 26: 67-76, 1988.
51. Hawgood BJ. Physiological and pharmacological effects of rattlesnake venoms. In: Tu AT (editor), Rattlesnake venoms: their applications and treatment, 121, Marcel Dekker, Inc., New York, 1982.
52. Kochwa S, Gitter S, Strauss A & Vriess A D. Immunologic study of Vipera xanthina palestinae venom and preparation of potent antivenin in rabbits. Journal of Immunology, 82: 107-114, 1959.
53. Ramlau J, Bock E & Fohlman J. Production of antivenom against detoxified taipoxin and immunochemical analysis of the α,β and γ subunits. Toxicon, 17: 43-48, 1979.
54. Liau My, Huang RJ & Chen SW. Enhancement of Naja naja atra antivenin production in horses. Chinese Journal of Microbiology and Immunology, 15: 294-299, 1982.
55. Chávez-Olórtegui C, Ait-Amara D, Rochat H, Diniz CR & Granier C. In vivo protection against scorpion toxins by liposomal immunization. Vaccine, 9: 907-911, 1991.
56. Fonseca SG, Ferreira AMM, Diniz CR & Chávez-Olórtegui C. Induction of neutralizing antibodies in mice immunized with scorpion toxins detoxified by liposomal entrapment. Brazilian Journal of Medical and Biological Research, (in press), 1997.
57. Freitas TV, Fortes-Dias CL & Diniz CR. Protection against the lethal effects of Crotalus durissus terrificus (South American rattlesnake) venom in animals immunized with crotoxin. Toxicon, 28: 1491-1496, 1990.
58. Rosenberg P. Phospholipases. In: Shier WT & Mebs D (Editors), Handbook of Toxinology, 67, Marcel Dekker, Inc., New York, 1990.
59. Freitas TV & Frezard F. Encapsulation of native crotoxin in liposomes: a safe approach for the production of antivenom and vaccination against Crotalus durissus terrificus venom. Toxicon, 35: 91-100, 1997.
60. De Haas Gh & van Deenem LLM. Structural identification of isomeric lysolecithins. Biochimica et Biophysica Acta, 106:315-318, 1965.
61. Freitas TV. Crotoxina, neurotoxina de veneno de Crotalus durissus terrificus, incorporada em liposomas (Ph. D thesis, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil), 1996.
62. Freitas TV, Fortes-Dias CL, Diniz CR, Velarde DT & Freitas CF. Immunization of horses with Crotalus durissus terrificus (South American rattlesnake) venom. A comparision of four different procedures. Brazilian Journal of Medical and Biological Research, 24: 281-290, 1991.
63. Bouwstra J A & Junginger H E. Non-ionic surfactant vesicles (niosomes) for oral and transdermal administration of drugs. In: Puisieux F, Couvreur P, Delattre J & Devissaguet JP (Editors), Liposomes, new systems and new trends in their applcations, 99, Editions de Santé, Paris, 1995.
64. Chien KY, Chiang CM, Hseu YC, Vyas AA, Rule GS & Wu WG. Two distinct types of cardiotoxin as revealed by the structure and activity relationship of their interaction with zwitterionic phospholipid dispersion. Journal of Biological Chemistry, 269: 14473-14483, 1994.
65. Bultrón E, Gutierrez JM & Thelestam M. Effects of Bothrops asper (Terciopelo) myotoxin III, a basic phospholipase A2, on liposomes and mouse gastrocnemius muscle. Toxicon, 31: 217-222, 1993.
66. 2 from Bothrops godmani (Godman's Pit Viper) snake venom. Archives of Biochemistry and Biophysics, 298: 135-142, 1992.
67. Patel TN, Braganca BM & Bellare RA. Changes produced by Cobra venom cytotoxin on the morphology of yoshida sarcoma cells. Experimental Cell Research, 57: 289-297, 1969.
68. 4 in liposomes. Biotechnology and Applied Biochemistry, 17: 31-36, 1993.